Kick start day two with clinical case study reviews, group discussion forums, and new updates on the full end-to-end drug development landscape for allogeneic cell therapies.
Leaders from; AgenTus, Bone Therapeutics, Bristol Myers Squibb and TCR2 will be showcasing:
- Novel strategies to overcome safety and tolerability risks
- Processes to achieve reproducibility and comparability in manufacture
- Experience navigating global regulatory challenges for off-the-shelf production
… and much more!
Key speakers include:
9:30 - 5:05 EDT | 6:30 - 2:05 PDT - All times are shown in EDT
9:30 am Virtual Coffee Networking Rooms
10:00 am Chair’s Opening Remarks
Keynote Clinical Case Studies
10:05 am Realizing the Clinical Potential of CRISPR/Cas9 for Best-in-Class Allogeneic Therapies
Synopsis
• Showcase clinical data from CTX110, CTX120 and CTX130 to review how allogeneic cells function in vivo
• Analayze depth of response, persistence and durability of the allogeneic cells to achieve complete responses
• How do allogeneic cells perform compared to autologous cell therapies?
10:35 am Learnings from Allogeneic CAR-T Clinical Trials
Synopsis
• Discussing patient conditioning without biologic immuno-depletion
• Outlining dosing considerations
• Evaluating cell expansion, persistence, and durability of response
11:05 am How an Effective Source Material Supply Chain Can Enhance Scalability of Cell and Gene Therapies
Synopsis
- Analyzing the impact of source material variability and characterization on downstream efficacy of cell therapy applications
- Utilizing reliable/recallable and dedicated donor pool strategies to ensure consistency and reproducibility
- Identifying how cell supply partners can help mitigate risk for clinical translation of allogeneic therapies
11:35 am Differentiated Non-Gene Edited Technologies to Generate Off-The-Shelf CAR-T Cells for the Treatment of Hematopoietic and Solid Malignancies
Synopsis
• Leveraging non-gene edited technologies to disrupt TCR signaling to generate allogeneic CAR T cells
• Exploiting natural receptor/ligand interactions for CAR T cell therapy of metastatic colorectal cancer
• Discussing the first-in-class shRNA-based BCMA-targeting allogeneic CAR T candidate for the treatment of multiple myeloma
12:05 pm Tech Slam – Benchmark Gold-Star Donor Material With Leading Blood Bank Providers
Synopsis
From Clinic to Commercial Reality: Leveraging Transplant Experience to Overcome Cell Therapy Supply Chain Hurdles
Joy Aho, Senior Product Manager, Be The Match BioTherapies
12:15 pm Refreshment Break
Synopsis
Take this time to follow up with your new connections with a 1-1 or group video call or take a break and make a coffee!
2:25 pm Refreshment Break
3.00PM Roundtable Discussion Session
Rob Igarashi, VP, Discovery & Pre-clinical Development, Kiadis Pharma
Christopher Kloss, Assistant Principal Scientist, Cell & Gene Therapy, Merck & Co
Innate Vs. Adaptive Immune Cell Types for Allogeneic Therapy
• Assess the different characteristics of NK, GDT and T cells and how this can impact their success as an allogeneic therapy
• Discuss current clinical and preclinical results, specifically assessing the potential to persist and safety profiles